Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Purified Vero Rabies Vaccine vs Imovax Rabies in Healthy Adults
NCT01877395Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2013
- Primary completion
- May 2014
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Rabies vaccine in rabies (2 arms), sponsored by Sanofi. Primary endpoints: Proportion of subjects achieving a rabies virus neutralizing antibody (RVNA) titer >= 0.5 IU/mL at Day 14 and Number of participants with rabies virus neutralizing antibody (RVNA) titer >= 0.5 IU/mL at Day 42. Started Jun 2013; status: completed.
02
Drugs
Rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on NCT01877395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01877395.